In summary, ACTN1 participated in the tumorigenesis and EMT of GC via the AKT/GSK3β/β-Catenin pathway and was correlated to poor prognosis, and could be a promising candidate for GC treatment. This evidence concerns the gene GSK3B and gastric cancer.